Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO131921 in Relapsed/Refractory CLL
NCT00496132Phase 2Terminated
- Sponsor
- Genentech
- Start
- Aug 2007
- Primary completion
- Jun 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of PRO131921 in chronic lymphocytic leukemia (CLL), sponsored by Genentech. Primary endpoint: Dose-limiting toxicities and adverse events. Started Aug 2007; status: terminated.
02
Drugs
PRO131921
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00496132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00496132.